QUIZ 4 - PIASCLEDINE

1. Osteoarthritis is characterized by joint pain & dysfunction

A. Degeneration of articular cartilage

B. Clinically characterized by usage-related pain and functional limitation

C. At advanced stages of disease (joint stiffness, muscle atrophy and limb deformity

D. All of the above

2. Incidence of OA increases dramatically with age and is worse for men.

A. True

B. False

3. Three (3) main structures are involved in development and progression of OA except:

A. Articular cartilage

B. Arthritic cartilage

C. Synovial membrane (synovium)

D. Subchondral bone

4. Piascledine® exerts a chondroprotective effect, by reducing the synthesis of inflammatory factors and proteases involved in cartilage degradation (prevent wear and tear) and helps fight osteoarthritis by increasing the synthesis of factors involved in cartilage regeneration, a process known as chondrostimulation (repair weakened cartilage).

A. True

B. False

5. The author of the ERADIAS study: Structure-modifying effect of PIASCLEDINE® in hip OA which run for 3 years is:

A. Christensen et al. 2008

B. Appelboom et al. 2001

C. Maheu et al. 2014

D. Blotman et al. 1997

6. Piascledine® is a combination of:

A. Soybean oil unsaponifiable 100mg + Avocado oil unsaponiafiable 200mg

B. Soybean oil unsaponifiable 200mg + Avocado oil unsaponiafiable 100mg

C. None of the above

7. Piacledine® have a strong clinical evidence to:

A. Restore function

B. Reduce pain

C. reduce NSAIDs use

D. All of the above

8. In controlled clinical trials demonstrate that, in patients with OA of the hip and/or knee, Piascledine®:

A. Reduces pain and improves disability

B. Reduces reliance on NSAIDs (NSAID-sparing effect) for pain relief

C. Reduces the progression of joint space narrowing in patients more severely affected by hip OA

D. Is safe and well-tolerated

E. All of the above

9. Piascledine® is manufactured by:

A. Church & Dwight Co., Inc. - USA

B. SMB Technology, S.A. - Belgium

C. Laboratoires EXPANSCIENCE - France

10. Piascledine® offers greater convenience to ensure faithful compliance to treatment of patients because:

A. It significantly reduces pain and functional impairment

B. It's once-a-day dosing

C. It has favorable tolerability profile

D. It significantly reduces patients’ need for NSAIDs